University of Florida

• B.S. Pharmacy, Shanghai Medical University
• M.S. Pharmaceutical Marketing, University of North Carolina at Chapel Hill, School of Pharmacy
• Ph.D. Health Economics/Health Services Research School of Public Health, University of North Carolina at Chapel Hill

Jianwei Xuan is the Director/Team Leader for Cancer, Respiratory, Ophthalmology, Endocrinology, and Allergy group at Pfizer Inc. He manages multiple therapeutic area teams to provide product oriented strategic outcomes research support to drive demand, support launch, and ensure access and reimbursement for Pfizer products. Before that Jianwei was a Director and Global lead for the Oncology, Musculoskeletal, & Inflammation Therapeutic Group at Glaxo Smithkline R&D. His duties have included directing and implementing health economic/outcomes research strategies and tactical plans to substantiate the value of GSK products, providing health economic input throughout product development life cycles, and assessing marketing positioning.

Before coming to USA, Jianwei worked in China’s Food and Drug Administration Bureau for 6 years. His area of experience including IND and NDA review.

Jianwei's master thesis was on the topic of "The Impact of Medicaid Pharmaceutical Prudent Purchasing Act 1990 on Drug Costs of Major Pharmacy Providers." He did his Ph.D. dissertation on the "Effects of Comorbidity on Health-related Quality of Life Measures (An analysis of multiple clinical trial data).

Jianwei is a member of many organizations including the Rho Chi Pharmacy Honor Society, the International Society for Quality of Life Research, the Society for Medical Decision Making, the International Society for Pharmacoeconomics and Outcomes Research, and the Chinese Pharmaceutical Society.

Selected Publications:

• Marton J, Enuha S. Boulanger L. Friedman M, Xuan, J, and menzin J. “National Estimates of Hospitalizations for Major Respiratory Conditions” Abstract presented at American College of Chest Physicians (ACCP) in Seattle, WA on 23-28 October 2004
• Menzin J, Boulanger L. Marton J. Friedman M, Dixon D. and Xuan, J. “National Estimates of Ambulatory Visits for Major Respiratory Conditions” Abstract presented at American College of Chest Physicians (ACCP) in Seattle, WA on 23-28 October 2004
• Enuha S. Marton J. Boulanger L. Friedman M, Xuan, J, and menzin J. “National Estimates of Work Loss for Major Respiratory Conditions” Abstract presented at American College of Chest Physicians (ACCP) in eattle, WA on 23-28 October 2004
• J. Menzin, Ph.D., J.S. Brown, Ph.D., M. Mannochia, Ph.D., B. Kitch, M.D., J.P. Marton, M.D., M. Friedman, M.D., and J. Xuan, “PREVALENCE AND AWARENESS OF RESPIRATORY DISEASE IN COMMUNITYSETTINGS: EARLY FINDINGS FROM THE RESPIRATORY HEALTH PROMOTION STUDY (RHPS)” Abstract submitted for 2005 ATS.
• Mohammad M. Najib, MBA, MPH; Renée J. Goldberg Arnold, PharmD; Diana J. Kaniecki, PharmD; Krista G. Pettit, PharmD; David Roth, MD; Laura Antell, MPH; Jianwei Xuan, PhD; "Medical Resource Use and Costs of Congestive Heart Failure Following Use of Carvedilol"; Heart Diseases (March/April/2002).
• Peter Panzarino, Jr, MD, Jianwei Xuan, PhD, “Economic Evaluation of Major Selective SerotoninReuptake Inhibitors in a Managed Care Population” Managed Care Interface, April 2001; 14(4) p59-65.
• Aileen B Luzier, Antell, L.A., Chang, L., Jianwei Xuan, and Roth D. "Reimbursement Claims Analysis of Outcomes with Carvedilol and Metoprolol"; The Annals of Pharmacotherapy, 2002 March, Vol. 36.
• Antell, L.A., Chang, L., Jianwei Xuan, and Roth D. "Reimbursement Claims Database Analysis of Economic and Clinical Outcomes with Carvedilol Versus Metoprolol Use in a Managed Care Heart Failure Population"; Abstratct presented at AHA. 2001.
• Jianwei Xuan , Phong Duong, Patricia A. Russo, Michael Lacey, Bruce Wong: "The Economic Burden of Congestive Heart Failure in a Managed Care Population". American Journal of Managed Care, June 2000; Vol. 6, No. 6; P 693-700.
• Jianwei Xuan, L. Kirchdoerfer, Greg Boyer, G. Joseph Norwood: "Effects of Comorbidity on Health-related Quality of Life (HRQOL) Scores: An Analysis of Clinical Trial Data". Clinical Therapeutics; Vol.21, NO.2, 1999. P383-403.
• Jianwei Xuan , et al.: “Utilization Pattern Reviews and Clinical, Economic Evaluation of Augmentin, Biaxin, and Zithromax for the Treatment of Bronchitis in Managed Care Organizations”. Abstract and paper in preparation.
• Jianwei Xuan , et al.: “Drug Utilization Review for newly Diagnosed Type 2 Diabetes Patients in Managed Care Organizations”. Abstract and paper submitted to AJMC.
• Duong PT, Jianwei Xuan et al.: “Economic Burden of Congestive Heart Failure in Managed Care” Abstract Book/ Association for Health Services Research. 14:156-157, 1998.
• Jianwei Xuan , G. Joseph Norwood: "Effects of Comorbidity and different statistical analysis coding methods on Health-related Quality of Life (HRQOL) Measures. Abstract and Podium Presentation; Southern Pharmacy Administration Conference; Gainesville FL; June 1994.
• Jianwei Xuan : " Drug Administration in Hospitals", a chapter in "Medical Health Administration in Industry" Ed. by Daoming Wang, Pub. by Shanghai People publish House, Shanghai, China 1989.
• Jianwei Xuan: "The Quantitative Analysis of Bi 3+ By Using Pocket Size Electrode Titration Instrument-Complex Reaction" Chinese Journal of Pharmaceutical Analysis 5(5):309-310, 1985.